BCL2 and diffuse large B-cell lymphoma: In support of our screening results, combinations with alternative compounds targeting aurora kinase (danusertib) and BCL2 (S55748) had combination benefit in DLBCL models WSU-DLCL2 and KARPAS422 (Supplementary Fig. S11A and S11B).